Clinical Trial Update: TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes. [Phase 4]

View source ↗

Summary

Phase 4 trial update for TriMaster evaluating a combination of a DPP-4 inhibitor, SGLT2 inhibitor, and thiazolidinedione as third-line therapy in adults with Ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• DPP-4 inhibitor
• SGLT2 inhibitor
• Thiazolidinedione (thiazolidinedione)

Snippet

Sponsor: Royal Devon and Exeter NHS Foundation Trust | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED